Hyperlawhypertext legal database Patent Act

← Historical versions

Versions of s. 83(4)

P-4 — Patent Act · 2 versions · View current text

Historical text comes from the Justice Laws point-in-time corpus and is unofficial — not the official version.

  1. 2024-08-19 to present available View Source
    WhereIf the Board, having regard to the extent and duration of the sales of the medicine at an excessive price, is of the opinion that the patenteerights holder or former patenteerights holder has engaged in a policy of selling the medicine at an excessive price, the Board may, by order, in lieu of any order it may make under subsection (2) or (3), as the case may be, direct the patenteerights holder or former patenteerights holder to do any one or more of the things referred to in that subsection asthat will, in the Board’s opinion, offset not more than twice the amount of the excess revenues estimated by it to have been derived by the patenteerights holder or former patenteerights holder from the sale of the medicine at an excessive price.
    Full text

    If the Board, having regard to the extent and duration of the sales of the medicine at an excessive price, is of the opinion that the rights holder or former rights holder has engaged in a policy of selling the medicine at an excessive price, the Board may, by order, in lieu of any order it may make under subsection (2) or (3), as the case may be, direct the rights holder or former rights holder to do any one or more of the things referred to in that subsection that will, in the Board’s opinion, offset not more than twice the amount of the excess revenues estimated by it to have been derived by the rights holder or former rights holder from the sale of the medicine at an excessive price.

  2. 2002-12-31 to present View Source

    Where the Board, having regard to the extent and duration of the sales of the medicine at an excessive price, is of the opinion that the patentee or former patentee has engaged in a policy of selling the medicine at an excessive price, the Board may, by order, in lieu of any order it may make under subsection (2) or (3), as the case may be, direct the patentee or former patentee to do any one or more of the things referred to in that subsection as will, in the Board’s opinion, offset not more than twice the amount of the excess revenues estimated by it to have been derived by the patentee or former patentee from the sale of the medicine at an excessive price.